Evelo Biosciences, Inc.

Equities

EVLO

US2997342025

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:55:59 2024-06-27 EDT			5-day change	1st Jan Change
0.0002 ^USD	-99.67%		0.00%	-99.67%

05-02	North American Morning Briefing : Stock Futures -2-	DJ
04-25	North American Morning Briefing : More Tech -2-	DJ

Evelo Biosciences, Inc. Eliminates Position of Jonathan Zung, Chief Development Officer

February 17, 2023 at 04:07 pm

On February 14, 2023, Jonathan Zung, Ph.D., the Chief Development Officer of Evelo Biosciences, Inc., was informed that his position was being eliminated in connection with the Company's previously announced cost savings initiatives. Dr. Zung is expected to serve in his position through March 3, 2023.

Latest news about Evelo Biosciences, Inc.

North American Morning Briefing : Stock Futures -2-	05-02	DJ
North American Morning Briefing : More Tech -2-	04-25	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	04-11	DJ
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
North American Morning Briefing : Investors -2-	03-21	DJ
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	12-14	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	12-11	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	12-11	CI
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	11-21	CI
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	11-21	CI
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	11-21	CI
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	23-10-18	MT
Sector Update: Health Care Stocks Retreat in Late Afternoon	23-10-17	MT
Sector Update: Health Care	23-10-17	MT
Top Midday Decliners	23-10-17	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	23-10-17	MT
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	23-10-17	MT
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	23-10-17	CI
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	23-10-10	MT
Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating	23-07-26	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	23-07-21	MT
Evelo Biosciences Signs Termination Agreement for Cambridge Office, Laboratory Space; Shares Up Premarket	23-07-21	MT

Chart Evelo Biosciences, Inc.

Duration

Period

More charts

Company Profile

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EVELO BIOSCIENCES, INC.	-99.67%	1.14M
VERTEX PHARMACEUTICALS INCORPORATED	+16.63%	122B
REGENERON PHARMACEUTICALS, INC.	+20.11%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.56%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-18.60%	15.49B
SAREPTA THERAPEUTICS, INC.	+62.01%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+2.72%	13.67B

Bio Therapeutic Drugs